Skip to Main Content

Sarepta Therapeutics said Monday that a second-generation medicine for patients with a certain type of Duchenne muscular dystrophy showed improved performance in laboratory tests over the biotech’s marketed treatment.

In a small clinical trial, a monthly infusion of the new Sarepta drug, called SRP-5051, produced eight times more of the muscle protein dystrophin compared to weekly infusions of Exondys 51, the company’s existing product.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!